Skip to main content
Search
Search
Advanced Search
Skip main navigation
Open access
Commentary
25 February 2022

Health technology assessments and real-world evidence: tell us what you want, what you really, really want

Authors: Frank Griesinger, Oliver Cox, Cormac Sammon, Sreeram V Ramagopalan [email protected], and Sanjay PopatAuthor Info & Affiliations
Volume 11, Number 5
https://doi.org/10.2217/cer-2021-0296
PDFFormats
First page of PDF

Formats available

You can view the full content in the following formats:

View PDFView Full Text

References

1.
Angelis A, Lange A, Kanavos P. Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries. Eur. J. Health Econ. 19(1), 123–152 (2018).
PubMed
Google Scholar
2.
Patel D, Grimson F, Mihaylova E et al. Use of external comparators for health technology assessment submissions based on single-arm trials. Value Health 24(8), 1118–1125 (2021).
PubMed
Google Scholar
4.
CADTH. common drug review – ocrelizumab (2017). https://cadth.ca/ocrelizumab
Google Scholar
5.
CADTH. common drug review – tocilizumab (2018). www.cadth.ca/index.php/tocilizumab-3
Google Scholar
6.
NICE. Technology appraisal guidance [TA518] – tocilizumab for treating giant cell arteritis (2018). www.nice.org.uk/guidance/ta518
Google Scholar
7.
NICE. Technology appraisal guidance [TA585] – ccrelizumab for treating primary progressive multiple sclerosis (2019). www.nice.org.uk/guidance/ta585.
Google Scholar
10.
IQWIG. Extract of dossier assessment A17-19 – Alectinib (non-small cell lung cancer) (2017). www.iqwig.de/download/a17-19_alectinib_extract-of-dossier-assessment_v1-0.pdf?rev=185028
Google Scholar
11.
Haute Autorité de Santé (HAS). Commission De La Transparence - Tisagenlecleucel (2018). www.has-sante.fr/upload/docs/application/pdf/2018-12/kymriah_ldgcb_pic_ins_avis3_ct17238.pdf
Google Scholar
12.
Norwegian Medicines Agency. Single Technology assessment - Tisagenlecleucel (Kymriah) for the treatment of second or later relapsed/refractory diffuse large B cell lymphoma (DLBCL) (2019). https://legemiddelverket.no/Documents/Offentlig%20finansiering%20og%20pris/Metodevurderinger/K/Kymriah_DLBCL_2019.pdf
Google Scholar
13.
Macdonald H, Goldacre B. Does the reformed cancer drug fund generate evidence on effectiveness? A cross-sectional analysis on publicly accessible documentation. medRxiv (2020) (Epub ahead of print).
Crossref
Google Scholar
14.
Sammon CJ, Leahy TP, Gsteiger S, Ramagopalan S. Real-world evidence and nonrandomized data in health technology assessment: using existing methods to address unmeasured confounding? J. Comp. Eff. Res. 9(14), 969–972 (2020).
PubMed
Google Scholar
15.
Brown JP, Douglas IJ, Hanif S, Thwaites RMA, Bate A. Measuring the effectiveness of real-world evidence to ensure appropriate impact. Value Health 24(9), 1241–1244 (2021).
PubMed
Google Scholar
16.
Carter P, Laurie GT, Dixon-Woods M. The social licence for research: why care.data ran into trouble. J. Med. Ethics 41(5), 404 (2015).
PubMed
Google Scholar
|